北京大学学报(医学版) ›› 2021, Vol. 53 ›› Issue (6): 1083-1087. doi: 10.19723/j.issn.1671-167X.2021.06.013

• 论著 • 上一篇    下一篇

系统性红斑狼疮患者血清白细胞介素-2受体α水平及其临床意义

田佳宜,张霞(),程功,刘庆红,王世阳,何菁()   

  1. 北京大学人民医院风湿免疫科,北京 100044
  • 收稿日期:2021-07-30 出版日期:2021-12-18 发布日期:2021-12-13
  • 通讯作者: 张霞,何菁 E-mail:haoxiamei@163.com;hejing1105@126.com
  • 基金资助:
    北京大学人民医院研究与发展基金(RS2020-01);国家自然科学基金(81601417)

Serum interleukin-2 receptor α as a clinical biomarker in patients with systemic lupus erythematosus

TIAN Jia-yi,ZHANG Xia(),CHENG Gong,LIU Qing-hong,WANG Shi-yang,HE Jing()   

  1. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China
  • Received:2021-07-30 Online:2021-12-18 Published:2021-12-13
  • Contact: Xia ZHANG,Jing HE E-mail:haoxiamei@163.com;hejing1105@126.com
  • Supported by:
    Peking University People’s Hospital Research and Development Funds(RS2020-01);National Natural Science Foundation of China(81601417)

摘要:

目的:探究系统性红斑狼疮(systemic lupus erythematosus,SLE)患者血清中白细胞介素-2受体α(interleukin-2 receptor α,IL-2Rα)水平在临床中的意义。方法:收集2019年1月至2020年12月就诊于北京大学人民医院的107例SLE患者病历资料,依据SLE疾病活动度指数(SLE disease activity index 2000,SLEDAI-2K)评估患者的病情活动情况,并选取年龄、性别分别匹配的39例健康人作为健康对照。采用酶联免疫吸附法测定SLE患者组和健康对照组的血清IL-2Rα水平,比较其差异并分析SLE患者IL-2Rα水平与临床指标及实验室指标的相关性。采用t检验或Mann-Whitney U检验、 χ2检验和Spearman秩相关性分析进行统计学分析。结果:SLE患者血清IL-2Rα水平[830.82(104.2~8 940.48) ng/L]较健康对照组[505.1(78.65~1 711.52) ng/L]明显升高(P<0.001)。相关性分析显示,血清IL-2Rα水平与SLEDAI-2K评分及抗核小体抗体滴度呈正相关(r=0.357,P<0.001;r=0.25,P=0.027)。107例SLE患者中36例(33.6%)合并狼疮性肾炎,合并狼疮性肾炎的患者血清IL-2Rα水平[1 102.14(126.52~8 940.48) ng/L]较未合并狼疮性肾炎患者[743.89(104.19~4 872.06) ng/L]明显升高(P=0.032)。高IL-2Rα水平组合并狼疮性肾炎者(40.8%)较低水平组(19.4%)明显升高(P=0.031),高IL-2Rα水平组SLEDAI-2K评分更高[10 (3~21) vs. 7 (3~16),P=0.001]。SLE患者常规治疗12周后血清IL-2Rα水平[1 119.1(372.25~2 608.86) ng/L]随病情改善较基线时[1 556.73 (373.08~8 940.48) ng/L]明显下降(P=0.042)。结论:血清IL-2Rα可作为SLE病情活动评估指标,与肾脏受累有一定相关性。

关键词: 受体, 白细胞介素-2, 红斑狼疮, 系统性, 狼疮肾炎, T淋巴细胞

Abstract:

Objective: To investigate the clinical relevance of serum interleukin-2 receptor α (IL-2Rα) in patients with systemic lupus erythematosus (SLE). Methods: One hundred and seven SLE patients and 39 healthy controls with comparable age and gender were recruited at Peking University People’s Hospital from January 2019 to December 2020. Complete clinical data in 107 SLE patients at baseline and follow-up were collected. SLE disease activity index 2000 (SLEDAI-2K) was used to assess the disease activity of the SLE patients. The serum level of IL-2Rα in the SLE patients and healthy controls was measured using enzyme-linked immunosorbent assay (ELISA). The association between serum IL-2Rα and clinical and laboratory parameters was investigated. Mann-Whitney U test or t test, Chi-square test and Spearman correlation were used for statistical analysis. Results: The serum IL-2Rα levels were significantly higher in the SLE patients [830.82 (104.2-8 940.48) ng/L], compared with those in the healthy controls [505.1 (78.65-1 711.52) ng/L] (P<0.001). Association analysis showed that the increased serum IL-2Rα was positively associated with SLEDAI-2K scores and anti-nucleosome antibody (r=0.357, P<0.001; r=0.25, P=0.027, respectively). Thirty-six of 107 (33.6%) SLE patients had lupus nephritis. Serum IL-2Rα levels were significantly higher in the patients accompanied with lupus nephritis [1 102.14 (126.52-8 940.48) ng/L] than in the patients without lupus nephritis [743.89 (104.19-4 872.06) ng/L] (P=0.032). The patients in the high IL-2Rα group had more lupus nephritis compared with those in the low IL-2Rα group (40.8% vs. 19.4%, P=0.031). Meanwhile, SLEDAI-2K scores were found significantly higher in the high IL-2Rα group than in the low IL-2Rα group [10 (3-21) vs. 7 (3-16), P=0.001]. With the improvement of disease activity in the SLE patients after conventional treatments, serum levels of IL-2Rα [1 119.1 (372.25-2 608.86) ng/L] in the week 12 decreased significantly compared with the baseline [1 556.73 (373.08-8 940.48) ng/L] (P=0.042). Conclusion: Serum IL-2Rα may be used as a biomarker of disease activity in patients with SLE. There is certain correlation between serum IL-2Rα and renal involvement in SLE.

Key words: Receptor, interleukin-2, Lupus erythematosus, systemic, Lupus nephritis, T-lymphocytes

中图分类号: 

  • R593.24

图1

血清IL-2Rα水平与临床相关性"

表1

IL-2Rα高水平组(≥590.48 ng/L)与低水平组(<590.48 ng/L)对比"

Items High IL-2Rα (n=71) Low IL-2Rα (n=36) P value
Gender,Female/Male 6/65 1/35 0.419
Age/year, median (range) 31 (18-66) 36 (29-52) 0.741
Duration/year, median (range) 2.0 (0.1-23.0) 2.0 (0.2-12.0) 0.355
LN, n (%) 29 (40.8) 7 (19.4) 0.031
SLEDAI-2K, median (range) 10 (3-21) 7 (3-16) 0.001
IgG/(g/L), median (range) 13.7 (1.9-35.9) 16.55 (8.2-29.9) 0.862
C3/(g/L), median (range) 0.453 (0.118-1.46) 0.656 (0.239-0.821) 0.685
C4/(g/L), median (range) 0.117 (0.04-0.544) 0.097 (0.032-0.227) 0.627
Anti-dsDNA/(IU/mL), median (range) 223.98 (25-1 845.6) 277.12 (20-1 665.8) 0.375
AnuA/(IU/mL), median (range) 133.87 (2-1 918.3) 85.72 (2-1 991.9) 0.197
ESR/(mm/h), median (range) 31 (6-110) 40 (11-42) 0.786
CRP/(mg/dL), median (range) 4.65 (1.05-93.2) 2.49 (1.03-10.8) 0.952

图2

血清IL-2Rα水平及SLEDAI-2K在SLE治疗前后的变化"

[1] Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus[J]. Nat Immunol, 2020, 21(6):605-614.
doi: 10.1038/s41590-020-0677-6
[2] Ross SH, Cantrell DA. Signaling and function of interleukin-2 in T lymphocytes[J]. Annu Rev Immunol, 2018, 36:411-433.
doi: 10.1146/immunol.2018.36.issue-1
[3] He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: A randomised, double-blind, placebo-controlled trial[J]. Ann Rheum Dis, 2020, 79(1):141-149.
[4] He J, Zhang X, Wei Y, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus[J]. Nat Med, 2016, 22(9):991-993.
doi: 10.1038/nm.4148
[5] Rubin L A, Galli F, Greene WC, et al. The molecular basis for the generation of the human soluble interleukin 2 receptor[J]. Cytokine, 1990, 2(5):330-336.
pmid: 2103332
[6] Dik WA, Heron M. Clinical significance of soluble interleukin-2 receptor measurement in immune-mediated diseases[J]. Neth J Med, 2020, 78(5):220-231.
[7] Luo H, Wang C, Feng M, et al. Microgravity inhibits resting T cell immunity in an exposure time-dependent manner[J]. Int J Med Sci, 2014, 11(1):87-96.
doi: 10.7150/ijms.7651
[8] El-Shafey EM, El-Nagar GF, El-Bendary AS, et al. Serum soluble interleukin-2 receptor alpha in systemic lupus erythematosus[J]. Iran J Kidney Dis, 2008, 2(2):80-85.
pmid: 19377213
[9] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40(9):1725.
[10] Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000[J]. J Rheumatol, 2002, 29(2):288-291.
pmid: 11838846
[11] Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: Updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)[J]. Arthritis Care Res (Hoboken), 2011, 63(Suppl 11):S37-S46.
doi: 10.1002/acr.v63.11s
[12] Russell SE, Moore AC, Fallon PG, et al. Soluble IL-2Rα (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice[J]. PLoS One, 2012, 7(10):e47748.
doi: 10.1371/journal.pone.0047748
[13] Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: From molecular mechanisms to human therapy[J]. Nat Rev Immunol, 2018, 18(10):648-659.
[14] Mizui M, Tsokos GC. Targeting regulatory T cells to treat patients with systemic lupus erythematosus[J]. Front Immunol, 2018(9):786.
[15] Laut J, Senitzer D, Petrucci R, et al. Soluble interleukin-2 receptor levels in lupus nephritis[J]. Clin Nephrol, 1992, 38(4):179-184.
pmid: 1424303
[1] 顾阳春,刘颖,谢超,曹宝山. 程序性死亡蛋白-1抑制剂治疗晚期肺癌出现垂体免疫不良反应3例[J]. 北京大学学报(医学版), 2022, 54(2): 369-375.
[2] 邹健梅,武丽君,罗采南,石亚妹,吴雪. 血清25-羟维生素D与系统性红斑狼疮活动的关系[J]. 北京大学学报(医学版), 2021, 53(5): 938-941.
[3] 李正芳,吴雪,武丽君,罗采南,石亚妹,钟岩,陈晓梅,孟新艳. Rhupus综合征的临床特点[J]. 北京大学学报(医学版), 2021, 53(5): 933-937.
[4] 马向波,张学武,贾汝琳,高颖,刘洪江,刘玉芳,李英妮. 外周血淋巴细胞亚群检测在系统性硬化症治疗中的应用[J]. 北京大学学报(医学版), 2021, 53(4): 721-727.
[5] 夏芳芳,鲁芙爱,吕慧敏,杨国安,刘媛. 系统性红斑狼疮伴间质性肺炎的临床特点及相关因素分析[J]. 北京大学学报(医学版), 2021, 53(2): 266-272.
[6] 廖栩鹤,王荣福,刘萌,陈雪祺,熊焰,农琳,殷雷,张炳晔,杜毓菁. 18F-FDG PET/CT半定量参数、表皮生长因子受体和间变淋巴瘤激酶基因突变对肺腺癌患者预后评估的价值[J]. 北京大学学报(医学版), 2021, 53(2): 246-254.
[7] 赵静,孙峰,李云,赵晓珍,徐丹,李英妮,李玉慧,孙晓麟. 抗α-1C微管蛋白抗体在系统性硬化症中的表达及临床意义[J]. 北京大学学报(医学版), 2020, 52(6): 1009-1013.
[8] 郭倩, 马晓旭, 高辉, 石连杰, 钟昱超, 谢琳峰, 邵苗, 张学武. Semaphorin 3A在系统性红斑狼疮合并血小板减少患者中的水平及意义[J]. 北京大学学报(医学版), 2020, 52(5): 892-896.
[9] 宋国红,李惠平,邸立军,严颖,姜晗昉,徐玲,万冬桂,李瑛,王墨培,肖宇,张如艳,冉然,王环. 真实世界吡咯替尼治疗HER2阳性转移性乳腺癌的疗效及安全性[J]. 北京大学学报(医学版), 2020, 52(2): 254-260.
[10] 耿研,李伯睿,张卓莉. 系统性红斑狼疮患者有症状关节病变的肌肉骨骼超声特点[J]. 北京大学学报(医学版), 2020, 52(1): 163-168.
[11] 何菁,程功,栗占国. 低剂量白细胞介素-2在自身免疫性疾病治疗中的意义及前景[J]. 北京大学学报(医学版), 2019, 51(6): 985-988.
[12] 李英妮,相晓红,赵静,李云,孙峰,王红彦,贾汝琳,胡凡磊. 抗类瓜氨酸化抗体在系统性红斑狼疮中的意义[J]. 北京大学学报(医学版), 2019, 51(6): 1019-1024.
[13] 张晓鹏,张维宇,霍飞,胡浩,王起,许克新. 原发性女性膀胱出口梗阻的手术疗效随访及其发病机制[J]. 北京大学学报(医学版), 2019, 51(6): 1052-1055.
[14] 王玉华,张国华,张令令,罗俊丽,高兰. 系统性红斑狼疮合并自发性肾上腺出血1例[J]. 北京大学学报(医学版), 2019, 51(6): 1178-1181.
[15] 梁学军,宫丽颖,周菲,周德敏,祝静静. 非天然氨基酸定点偶联抗人类表皮生长因子受体2-抗体偶联药物的药理学活性[J]. 北京大学学报(医学版), 2019, 51(5): 797-804.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 张三. 中文标题测试[J]. 北京大学学报(医学版), 2010, 42(1): 1 -10 .
[2] 赵磊, 王天龙 . 右心室舒张末期容量监测用于肝移植术中容量管理的临床研究[J]. 北京大学学报(医学版), 2009, 41(2): 188 -191 .
[3] 万有, , 韩济生, John E. Pintar. 孤啡肽基因敲除小鼠电针镇痛作用增强[J]. 北京大学学报(医学版), 2009, 41(3): 376 -379 .
[4] 张燕, 韩志慧, 钟延丰, 王盛兰, 李玲玲, 郑丹枫. 骨骼肌活组织检查病理诊断技术的改进及应用[J]. 北京大学学报(医学版), 2009, 41(4): 459 -462 .
[5] 赵奇, 薛世华, 刘志勇, 吴凌云. 同向施压测定自酸蚀与全酸蚀粘接系统粘接强度[J]. 北京大学学报(医学版), 2010, 42(1): 82 -84 .
[6] 林红, 王玉凤, 吴野平. 学校生活技能教育对小学三年级学生行为问题影响的对照研究[J]. 北京大学学报(医学版), 2007, 39(3): 319 -322 .
[7] 丰雷, 程嘉, 王玉凤. 注意缺陷多动障碍儿童的运动协调功能[J]. 北京大学学报(医学版), 2007, 39(3): 333 -336 .
[8] 李岳玲, 钱秋瑾, 王玉凤. 儿童注意缺陷多动障碍成人期预后及其预测因素[J]. 北京大学学报(医学版), 2007, 39(3): 337 -340 .
[9] . 书讯[J]. 北京大学学报(医学版), 2007, 39(3): 225 -328 .
[10] 牟向东, 王广发, 刁小莉, 阙呈立. 肺黏膜相关淋巴组织型边缘区B细胞淋巴瘤一例[J]. 北京大学学报(医学版), 2007, 39(4): 346 -350 .